Table 1. Baseline Characteristics of Reasons for Geographic and Racial Differences in Stroke Study Participants in the Cohort Random Sample Weighted Back to Original Cohort Overall and by Quartiles of Fibroblast Growth Factor 23 (FGF23).
| Characteristic | Mean (95% CI) | ||||
|---|---|---|---|---|---|
| Overall | FGF23 Concentration | ||||
| Quartile 1 (<53 RU/mL) | Quartile 2 (53-70 RU/mL) | Quartile 3 (>70-100 RU/mL) | Quartile 4 (>100 RU/mL) | ||
| Participants, weighted No. | 22 127 | 5764 | 5870 | 5530 | 4962 |
| Age, y | 64.3 (63.7-64.9) | 62.1 (60.9-63.1) | 63.4 (62.2-64.6) | 65.4 (64.2-66.6) | 66.5 (65.2-67.9) |
| Female, % | 58.9 | 44.4 | 58.3 | 57.3 | 78.6 |
| Black, % | 42.6 | 49.1 | 39.2 | 45.3 | 36.1 |
| Body mass indexa | 29.4 (28.9-29.8) | 28.5 (27.7-29.4) | 29.4 (28.4-30.4) | 29.9 (28.9-30.8) | 29.6 (28.5-29.5) |
| Waist circumference, cm | 95.2 (93.9-96.4) | 93.7 (91.6-95.9) | 95.3 (92.6-98.1) | 96.8 (94.7-98.8) | 95.1 (92.5-97.6) |
| Systolic blood pressure level, mm Hg | 126.9 (125.6-128.1) | 128.4 (125.4-131.3) | 125.6 (123.6-127.7) | 126.6 (123.8-129.4) | 126.8 (124.4-129.1) |
| Diastolic blood pressure level, mm Hg | 76.7 (75.9-77.4) | 78.1 (76.7-79.5) | 76.9 (75.5-78.4) | 76.5 (74.8-78.2) | 74.9 (73.5-76.3) |
| Less than high school education, % | 11.0 | 12.4 | 9.2 | 10.5 | 12.1 |
| Annual income <$20 000/y, % | 15.4 | 14.5 | 10.9 | 17.6 | 19.4 |
| Comorbidities, % | |||||
| Current smoking | 13.3 | 10.8 | 7.9 | 15.6 | 20.2 |
| Diabetes | 18.9 | 17.4 | 14.8 | 20.7 | 23.3 |
| Left ventricular hypertrophy | 7.3 | 5.2 | 5.8 | 9.6 | 8.9 |
| Medications | |||||
| Statins | 27.4 | 27.3 | 25.8 | 23.8 | 33.2 |
| RAAS inhibitors | 28.7 | 29.3 | 21.6 | 25.4 | 40.3 |
| Aspirin | 39.0 | 40.6 | 34.5 | 35.4 | 46.5 |
| Hormone therapyb | 55.8 | 51.0 | 56.3 | 52.6 | 61.2 |
| Laboratory values | |||||
| eGFR, mL/min/1.73 m2 | 87.3 (85.8-88.7) | 93.8 (91.3-96.3) | 89.8 (87.4-92.3) | 86.8 (84.0-89.5) | 77.4 (74.2-80.6) |
| UACR, mg/g | 6.9 (4.4-13.8) | 6.4 (4.0-12.6) | 6.6 (4.2-11.1) | 7.3 (5.1-14.8) | 8.9 (4.5-20.6) |
| HDL-C level, mg/dL | 52.6 (51.3-53.9) | 53.7 (51.2-56.3) | 51.8 (49.3-54.3) | 51.6 (48.4-54.8) | 53.4 (50.8-55.9) |
| Triglyceride concentration, mg/dL | 131.1 (125.0-137.1) | 116.5 (106.6-126.4) | 125.9 (115.7-136.2) | 139.9 (126.3-153.6) | 144.0 (130.1-157.9) |
| Total cholesterol level, mg/dL | 192.9 (189.8-196.2) | 192.2 (186.1-198.4) | 196.1 (190.2-202.1) | 193.9 (186.4-201.4) | 189.2 (183.1-195.3) |
| Serum parathyroid hormone level, pg/mL | 45.7 (43.9-47.4) | 40.3 (37.9-42.8) | 45.5 (42.7-48.3) | 49.9 (46.2-53.7) | 47.2 (42.4-52.1) |
| C-reactive protein level, mg/L | 2.1 (0.9-4.7) | 1.7 (0.7-3.8) | 1.8 (0.9-3.7) | 2.6 (1.1-5.4) | 2.7 (1.1-5.5) |
Abbreviations: eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; RAAS, renin-angiotensin-aldosterone system; RU, relative unit; UACR, urine albumin to creatinine ratio.
a
Body mass index calculated as weight in kilograms divided by height in meters squared.
b
Only in women in the random cohort with available data (weighted n = 12 941).